To: 5.1.2e [5.1.2e @rivm.nl]; 5.1.2e [5.1.2e @rivm.nl]; 5.1.2e 5.1.2e [5.1.2e @rivm.nl]; 5.1.2e [5.1.2e @rivm.nl]; 5.1.2e [5.1.2e @rivm.nl]; 5.1.2e [5.1.2e @rivm.nl]; 5.1.2e [5.1.2e @rivm.nl]; 5.1.2e [5.1.2e @rivm.nl]; 5.1.2e [5.1.2e @rivm.nl]; 5.1.2e [5.1.2e @rivm.nl]
Cc: 5.1.2e [5.1.2e @rivm.nl]; 5.1.2e [5.1.2e @rivm.nl]; 5.1.2e [5.1.2e @rivm.nl]; 5.1.2e [5.1.2e @rivm.nl]; 5.1.2e [5.1.2e @rivm.nl]
From: 5.1.2e
Sent: Mon 12/21/2020 4:48:11 PM
Subject: Input highly appreciated!
Received: Mon 12/21/2020 4:48:12 PM
Short version_protocol SARS-CoV-2 vaccines_v2.rtf

Hi project leaders,

As 5.1.2e announced in her email, your input would be highly appreciated for our new IIV protocol. Please find in attachment a summary of the protocol to give you an idea on general objectives/endpoints.

5.1.2e and I would be very much helped if you could reply to 5.1.2e and me (not reply all), with a Word document (e.g. ½ A4) consisting of:

- The endpoints you would study
- The timepoints you would prefer for sampling
- Short summary of assays you would perform
- Some introductory remarks in 2-3 sentences with 1-2 key references in your field why this should be studied – would give enormous speed to further writing the introduction
- Funny ideas for an acronym for the study are of course very welcome

If you are currently involved in other protocols such as VOICE or Target2Be, please try to harmonize your sampling (timepoints, assays) with these protocols. It would have a great impact in a future phase to be able to compare studies and populations.

As 5.1.2e mentioned, the current groups are as follows:
-Antibodies in serum and saliva (levels, kinetics, specificity, avidity): 5.1.2e
-Innate response: 5.1.2e
-T cells/B cells: 5.1.2e
-Ab functionality: 5.1.2e
-Microbiome: 5.1.2e
@ 5.1.2e we are in fact not sure we should include feces sampling in this study or whether it would be far more efficient to include it in an amendement for an ongoing cohort. If you are not on holidays, could you please contact me so we can discuss your ideas in more detail?
@ Everyone, please consult the colleagues whom you think should give input on your topic and who are not on annual leave – but let's keep this a general protocol. As 5.1.2e said, in January we will further align on who has time to do what and when and how.

Thanks so much in advance for your input! If you are unable to provide input before this weekend, which would be very understandable, please be so kind as to inform me and I will contact someone else.

Kind regards,
5.1.2e

Met vriendelijke groet, kind regards,
5.1.2e

5.1.2e
5.1.2e
Centre for Immunology of Infectious Diseases and Vaccines
RIVM, Centre for Infectious Disease Control (CIb)
PO Box 1, 3720 AL Bilthoven, The Netherlands
T +31 (0)6 5.1.2e